Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEpe Special Opp Regulatory News (ESO)

Share Price Information for Epe Special Opp (ESO)

Share Price is delayed by 15 minutes
Get Live Data
237.00    0.00 (0.00%)
Bid:
232.00
Ask:
242.00
Spread: 10.00 (4.31%)
Market Cap: £58.41m
ESO Live PriceLast checked at - London Stock Exchange

Intraday Epe Special Opp Share Chart

Investment

7 Oct 2022 08:00

RNS Number : 1502C
EPE Special Opportunities Limited
07 October 2022
 

EPE Special Opportunities Limited

 

Investment

 

EPE Special Opportunities Limited ("ESO" or the "Company") is pleased to announce that ESO Investments 1 Limited (an undertaking of ESO, in which it is the sole investor) ("ESO 1") has completed a £2.0 million growth capital investment into Denzel's Limited ("Denzel's").

 

Denzel's is a fast-growing, healthy and sustainable premium dog snacks brand. Denzel's products are made in the UK and Ireland using entirely natural ingredients and 100% plastic-free eco-friendly packaging.

 

Denzel's operates an omni-channel distribution strategy, underpinned by listings in some of the UK's leading retailers including Tesco, Sainsbury's, Asda, Wilko, SPAR and, most recently, Waitrose, which launched the Denzel's range in October. Denzel's launched its new website in late August (www.denzels.co.uk), which is the flagship of its online channel, complemented by listings on both Amazon and Ocado, allowing for direct-to-home delivery of its products as well as subscriptions. In addition, Denzel's products are available in a range of hospitality locations, notably dog-friendly pubs and hotels across the UK, providing dog owners with access to Denzel's for their dogs when they are out and about. Denzel's products are currently stocked in over two thousand locations in the UK.

 

Denzel's is part of the current cohort of the Tesco Incubator Programme, which helps to accelerate best-in-class brands using Tesco's retail infrastructure. Alumni brands include the premium mixers brand Fever-Tree, performance nutrition brand Grenade and the healthy food brand Deliciously Ella.

 

ESO intends to work closely with Denzel's to help deliver its growth strategy, which is focused on the launch of new products, notably high value and functional dog treats, as well as growth of both offline and online distribution channels.

 

ESO 1's £2.0 million investment was part of a £3.0 million growth capital raise by Denzel's, in which ESO 1 was the lead investor.

 

ESO 1's investment in Denzel's was funded by cash reserves advanced from ESO. Following the investment, ESO has available cash of £21.8 million. The investment in Denzel's has no impact on the Company's net asset value.

 

The investment in Denzel's is consistent with ESO's focus on investing into small and medium sized enterprises ("SMEs"), partnering with management teams to create value through long-term business transformation.

 

About ESO

 

ESO is an AIM-quoted, private equity investment company, whose objective is to provide long-term return on equity for its shareholders by investing in SMEs.

 

ESO seeks to invest up to £30 million into companies with strong fundamentals, including defensible competitive positioning and high levels of cash generation, and aims to partner with outstanding management teams to combine operational and financial expertise in each investment.

 

ESO will consider most industry sectors, including consumer, retail, manufacturing, financial services and the broader services sectors, and can make direct investments, special situations investments, primary and secondary fund investments and private investments in public equities.

 

ESO's investment horizon is flexible, creating the opportunity to maximise value via optimising exit timing, compounding returns and re-investing behind successful management teams.

 

The person responsible for releasing this information on behalf of the Company is Amanda Robinson of Langham Hall Fund Management (Jersey) Limited.

 

Enquiries:

 

EPIC Investment Partners LLP

+44 (0) 207 269 8865

James Henderson

 

Langham Hall Fund Management (Jersey) Limited

+44 (0) 153 488 5200

Amanda Robinson

 

Cardew Group Limited

+44 (0) 207 930 0777

Richard Spiegelberg

 

Numis Securities Limited

+44 (0) 207 260 1000

Nominated Advisor:

Stuart Skinner 

Corporate Broker:

Charles Farquhar

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMRBFTMTAMMLT
Date   Source Headline
5th Jun 20265:20 pmRNSUpdate on Share Buy Backs
5th Jun 20267:00 amRNSNet Asset Value(s)
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20265:00 pmRNSHolding(s) in Company
1st Jun 20264:25 pmRNSTransaction in Own Shares
1st Jun 20267:00 amRNSAnnouncement of Share Buy Backs
29th May 20261:30 pmRNSDirector/PDMR Shareholding
27th May 20264:00 pmRNSPartial Sell Down of Investment in Luceco plc
8th May 20267:00 amRNSNet Asset Value(s)
28th Apr 20265:05 pmRNSHolding(s) in Company
28th Apr 20265:00 pmRNSDirector/PDMR Shareholding
28th Apr 20267:15 amRNSDirector/PDMR Shareholding
23rd Apr 20267:15 amRNSHolding(s) in Company
16th Apr 20262:50 pmRNSHolding(s) in Company
16th Apr 20262:45 pmRNSDirector/PDMR Shareholding
15th Apr 20269:12 amRNSNet Asset Value(s)
14th Apr 20267:00 amRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSDirector/PDMR Shareholding
25th Mar 20267:00 amRNSAnnual Financial Report
20th Feb 20266:22 pmRNSUpdate on Share Buy Backs
18th Feb 20261:00 pmRNSTransaction in Own Shares
17th Feb 20265:10 pmRNSHolding(s) in Company
17th Feb 20265:00 pmRNSHolding(s) in Company
17th Feb 20261:35 pmRNSTransaction in Own Shares
13th Feb 20267:00 amRNSAnnouncement of Share Buy Backs
9th Feb 20267:00 amRNSTrading Statement
4th Feb 20267:00 amRNSInterest Payment on Unsecured Loan Notes
15th Jan 20267:00 amRNSNet Asset Value(s)
22nd Dec 20257:00 amRNSUpdate on Share Buy Backs
22nd Dec 20257:00 amRNSUpdate on Share Buy Backs
11th Dec 20257:00 amRNSNet Asset Value(s)
4th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:03 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:08 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSNet Asset Value(s)
13th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 20257:00 amRNSDirector/PDMR Shareholding
17th Oct 20257:00 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.